HB
Helix BioPharma Corp.
HBPCF · OTC
$1.71 +0.00% (+$0.00)
Market Cap $179.9M
P/E Ratio -
Div. Yield -
ROE 21.90%
Bulios Fair Price
$0.99
42.1% downside
Current Price
$1.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HBPCF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 12.25x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 264.91%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 22.04%
ROE 21.90%
ROA 15.78%
Debt
47 /100
Moderate Debt/Equity 0.02x
Current ratio 0.45x
Int. coverage -130.06x
Stability
39 /100
Moderate Beta -0.35x
EPS volatility 42.79%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HBPCF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Thomas Mehrling
Employees
7
Headquarters
Vancouver
Upcoming events
29 OCT
Earnings
Upcoming earnings report